FDA Warning Letter Reveals Critical Data Integrity Failures at Genzyme
The FDA has issued a warning letter to Sanofi following an inspection of its Genzyme manufacturing facility in Waterford, Ireland. The letter, dated June 22 and released this week, outlines multiple concerns related to data integrity and quality system performance. According to the agency, inspectors identified deficiencies that affected laboratory documentation practices, record traceability, and the management of quality-related events.
Why the FDA Questioned Genzyme’s Laboratory Review and Record Traceability
One of the FDA’s main observations focused on the site’s data integrity controls. Inspectors concluded that the facility’s data integrity program did not operate as represented. During the January inspection, quality control personnel used uncontrolled review checklists to unofficially document laboratory record reviews before discarding them. In addition, some updates made to laboratory records could not be traced to a specific individual. Therefore, the FDA questioned whether the facility maintained complete, attributable, and reliable records in accordance with GMP expectations.
Cancelled Deviations Became a Major Quality System Concern
The warning letter also highlighted deficiencies in the facility’s deviation management process. According to the FDA, several quality-related deviations were canceled without appropriate investigation. The agency explained that these quality events required formal assessment before closure, yet the site closed them without sufficient review. As a result, inspectors raised concerns about the effectiveness of the site’s overall quality system.
Sanofi Responds While FDA Challenges the Company’s Quality Assessment
Sanofi said it takes the warning letter seriously and has already started implementing corrective actions to address every observation. The company also stated that it does not expect the warning letter to affect drug supplies from the Waterford fill-and-finish facility, where approximately 450 employees manufacture Cerezyme, Fabrazyme, and Lumizyme.
Following the January inspection and in response to the earlier Form 483 observations, Genzyme completed a retrospective review of 74 canceled deviations identified during the inspection. The company determined that 36 of those cases required further investigation.
What This FDA Warning Letter Means for GMP Compliance and Data Integrity
Although Genzyme concluded that the canceled deviations had no impact on product quality, the FDA found that conclusion insufficiently supported. The agency noted that several canceled deviations involved failures to meet reject limits, missed secondary reviews, and other quality-related events that required investigation. Because the facility closed those deviations without adequate assessment, the FDA determined that the company had not demonstrated effective oversight of its quality system.
The warning letter highlights the FDA’s continued emphasis on data integrity, documentation integrity, and robust deviation investigations as essential elements of GMP compliance. For pharmaceutical manufacturers, the inspection serves as another reminder that traceable records, documented investigations, and consistently executed quality systems remain critical during regulatory inspections.
This inspection highlights how weak deviation management, incomplete investigations, and poor record traceability can quickly become major GMP compliance risks. If your organization is strengthening its Pharmaceutical Quality Management System, Zamann Pharma Support provides hands-on QMS services that help teams improve everyday quality processes, maintain inspection readiness, and build sustainable GMP compliance.
Source: EndpointsNews.Com